Figures computed from official regulatory filings — .
Analysttarget 15.5 USD (+84%) · consensus 5/5 · 5 buy · 0 hold · 0 sell
Ownershipinsiders 27.83% · institutions 40.91% · short 15.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for DiaMedica Therapeutics Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
69 buys1 sell— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Pauls Dietrich Johntrack record | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parsons James T. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kellen Scotttrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lewis Tanya | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Pauls Dietrich Johntrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kuntz Richard | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| O'Connor Danieltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Giuffre Randall Michaeltrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Krop Julie | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Semba Charles Pauling | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Giuffre Randall Michaeltrack record | Award | $52K | SEC |
| Semba Charles Pauling | Award | $28.2K | SEC |
| Parsons James T. | Award | $85K | SEC |
| TRILL ABtrack record | Buy | $626.5K | conv 17 | SEC |
| TRILL ABtrack record | Buy | $317.6K | conv 17Unusual size | SEC |
| TRILL ABtrack record | Buy | $1.5M | conv 12 | SEC |
| TRILL ABtrack record | Buy | $1.2M | conv 31First in 12mo | SEC |
| TRILL ABtrack record | Buy | $951.6K | conv 6 | SEC |
| TRILL ABtrack record | Buy | $1.2M | conv 23 | SEC |
| TRILL ABtrack record | Buy | $1.7M | conv 24 | SEC |
| Parsons James T. | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Parsons James T. | Exercise | $26.4K | SEC |
| Krop Julie | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| STAHLBERG JANtrack record | Buy | $416.7K | conv 30Cluster | SEC |
| STAHLBERG JANtrack record | Buy | $304.6K | conv 30Cluster | SEC |